KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gilead Sciences (GILD) Operating Expenses (2016 - 2025)

Gilead Sciences' Operating Expenses history spans 17 years, with the latest figure at $5.9 billion for Q4 2025.

  • For Q4 2025, Operating Expenses rose 16.1% year-over-year to $5.9 billion; the TTM value through Dec 2025 reached $19.4 billion, down 28.31%, while the annual FY2025 figure was $19.4 billion, 28.31% down from the prior year.
  • Operating Expenses reached $5.9 billion in Q4 2025 per GILD's latest filing, up from $4.4 billion in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $11.0 billion in Q1 2024 to a low of $3.5 billion in Q1 2021.
  • Average Operating Expenses over 5 years is $5.2 billion, with a median of $4.6 billion recorded in 2023.
  • Peak YoY movement for Operating Expenses: skyrocketed 136.88% in 2024, then plummeted 59.76% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $6.3 billion in 2021, then decreased by 18.75% to $5.1 billion in 2022, then increased by 7.42% to $5.5 billion in 2023, then dropped by 7.0% to $5.1 billion in 2024, then grew by 16.1% to $5.9 billion in 2025.
  • Per Business Quant, the three most recent readings for GILD's Operating Expenses are $5.9 billion (Q4 2025), $4.4 billion (Q3 2025), and $4.6 billion (Q2 2025).